dotMD.com
Find a Doctor
✓ Translated by DotMD AI Clinical Council Source: ClinicalTrials.gov Registry (NIH NLM) • Completed Human Clinical Trial (NCT)
Verify Primary Source: NIH PubMed PMID #NCT03396211
Plain-English Research Story • 8th-Grade Reading Level

Can This Approach Help? Inside the Latest Research on An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer. Total study duration will be approximately

Original Paper Title: “An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer” (ClinicalTrials.gov Registry (NIH NLM), 2022-03-16)

Elena Rostova (AI Quant) Rigor Score
89 / 100
Sample Size (Participants)
N = 30
Evidence Classification
Completed Human Clinical Trial (NCT)
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatment and subsequent survival follow up.
  • Who Was Studied: Completed Human Clinical Trial (NCT) published in ClinicalTrials.gov Registry (NIH NLM) following 30 real-world participants.
  • Strength of the Evidence: Earned a 89/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer. Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatment and subsequent survival follow up. Registered in the U.S. National Library of Medicine ClinicalTrials.gov v2 registry (NCT03396211).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in ClinicalTrials.gov Registry (NIH NLM) (2022-03-16) • Study Design: Completed Human Clinical Trial (NCT) • Participants: N = 30 • Biostatistical Rigor Score: 89/100. Primary Takeaway: Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatment and subsequent survival follow up.

Study Limitations & Caveats Before You Act

While this completed human clinical trial (nct) scored 89/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer”
Published in ClinicalTrials.gov Registry (NIH NLM) (2022-03-16) • PMID/ID: NCT03396211
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Rx: nivolumab-and-hyaluronidase-nvhy → Condition: cancer → Condition: safety →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID NCT03396211: Can This Approach Help? Inside the Latest Research on An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of

3 of 3 Free Questions Remaining